Keith Flaherty is Director of Clinical Research at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School.
[1] He was previously a professor of medicine at the University of Pennsylvania.
He is known for his research on targeted therapies for cancer, and in particular for his work on the melanoma drug vemurafenib.
[2][3][4][5] In 2013, Massachusetts General Hospital partnered with AstraZeneca to partner Flaherty's research into developing a formula to identify vulnerabilities of tumors with AstraZeneca's library of drugs.
[6]